Literature DB >> 7759996

Polymorphism of human minor histocompatibility antigens: T cell recognition of human minor histocompatibility peptides presented by HLA-B35 subtype molecules.

Y Beck1, L Satz, Y Takamiya, S Nakayama, L Ling, Y Ishikawa, T Nagao, H Uchida, K Tokunaga, C Müller.   

Abstract

To investigate the polymorphism of human minor histocompatibility (mH) antigens, PBLs from 23 Japanese individuals and 25 German individuals with HLA-B35 were studied by using four human mH antigen-specific, HLA-B35-restricted CTL clones. The CTL clones killed PHA-stimulated PBLs from all 23 Japanese individuals. On the other hand, they killed the PHA-stimulated PBLs from 19 of 25 German individuals and partially killed the PHA-stimulated PBLs from three German individuals (CTL weakly sensitive cell line); those from another three individuals (CTL-resistant cell line) were not killed by the CTL clones. All of three CTL weakly sensitive cell lines carry HLA-B*3503 molecules, whereas the three CTL-resistant cell lines carry HLA-B*3502, B*3507, and B*3508 molecules. The cytotoxicity of the CTL clones for three CTL weakly sensitive cell lines was enhanced by stimulation of human mH peptides isolated from HLA-B*3501 molecules purified from C1R-B*3501 cells. Small amounts of human mH peptides were isolated from B*3503 molecules purified from these three CTL weakly sensitive cell lines. Taken together, these results indicate that weak recognition by the CTL clones of three CTL weakly sensitive cell line results from a small amount of the human mH peptides presented by B*3503 molecules. The CTL-resistant cell line carrying B*3507 loaded with the human mH peptides was killed by four CTL clones, whereas the cell lines carrying B*3502 or B*3508 loaded with the peptides were not. The human mH peptides were not isolated from B*3507 molecules purified from the cell lines expressing this subtype, whereas small amounts of the human mH peptides were isolated from B*3502 and B*3508 molecules purified from the cell lines expressing the subtypes. These results indicate that failure of the CTL recognition of the cell line carrying B*3507 is due to a lack of human mH antigens in this cell line. The failure of the CTL recognition of the cell lines carrying B*3502 and B*3508 is not explained by only the amount of the human mH peptides binding to these B35 subtype molecules because the amount of the human mH peptides eluted from B*3502 and B*3508 molecules purified from the cell lines carrying these B35 subtypes is almost the same as that eluted from B*3503 molecules purified from the cell lines carrying B*3503.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7759996      PMCID: PMC2192060          DOI: 10.1084/jem.181.6.2037

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  41 in total

1.  Site-directed mutagenesis of an HLA-A3 gene identifies amino acid 152 as crucial for major-histocompatibility-complex-restricted and alloreactive cytotoxic-T-lymphocyte recognition.

Authors:  E P Cowan; M L Jelachich; J E Coligan; W E Biddison
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

2.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

3.  Brefeldin A implicates egress from endoplasmic reticulum in class I restricted antigen presentation.

Authors:  J G Nuchtern; J S Bonifacino; W E Biddison; R D Klausner
Journal:  Nature       Date:  1989-05-18       Impact factor: 49.962

4.  Structure of the human class I histocompatibility antigen, HLA-A2.

Authors:  P J Bjorkman; M A Saper; B Samraoui; W S Bennett; J L Strominger; D C Wiley
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

5.  Primary in vitro generation of cytotoxic cells specific for human minor histocompatibility antigens between HLA-identical siblings.

Authors:  W A Tekolf; S Shaw
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

6.  Description of monoclonal antibody defining an HLA allotypic determinant that includes specificities within the B5 cross-reacting group.

Authors:  B F Haynes; E G Reisner; M E Hemler; J L Strominger; G S Eisenbarth
Journal:  Hum Immunol       Date:  1982-07       Impact factor: 2.850

7.  Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes.

Authors:  J W Yewdell; J R Bennink
Journal:  Science       Date:  1989-06-02       Impact factor: 47.728

8.  Alloreactive T cell responses between HLA-identical siblings. Detection of anti-minor histocompatibility T cell clones induced in vivo.

Authors:  C Irle; P G Beatty; E Mickelson; E D Thomas; J A Hansen
Journal:  Transplantation       Date:  1985-09       Impact factor: 4.939

9.  A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease.

Authors:  E Goulmy; J W Gratama; E Blokland; F E Zwaan; J J van Rood
Journal:  Nature       Date:  1983-03-10       Impact factor: 49.962

10.  Molecular cloning and DNA sequence analysis of genes encoding cytotoxic T lymphocyte-defined HLA-A3 subtypes: the E1 subtype.

Authors:  E P Cowan; B R Jordan; J E Coligan
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

View more
  3 in total

1.  Complete sequence of a new HLA-B35 allele found in a tribe of Mapuche Indians in the south of Argentina.

Authors:  G C Theiler; Y C Marcos; E Kolkowski; N Lindel; M Capucchio; P Barrionuevo; F R Carnese; M L Satz
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

2.  Motif of HLA-B*3503 peptide ligands.

Authors:  A Steinle; K Falk; O Rötzschke; V Gnau; S Stevanović; G Jung; D J Schendel; H G Rammensee
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

3.  Zooming into the binding groove of HLA molecules: which positions and which substitutions change peptide binding most?

Authors:  Hanneke W M van Deutekom; Can Keşmir
Journal:  Immunogenetics       Date:  2015-06-04       Impact factor: 2.846

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.